Open Access

Comparative hematological profiles for dose‑dense vs. regular anthracycline‑based neoadjuvant chemotherapy in non‑metastatic breast cancer

  • Authors:
    • Dorel Popovici
    • Cristina Oprean
    • Sorin Săftescu
    • Alina Negru
    • Mihnea Muntean
    • Horia T. Stanca
    • Adrian Teodoru
    • Simona Stanca
    • Șerban Negru
  • View Affiliations

  • Published online on: May 11, 2021     https://doi.org/10.3892/etm.2021.10179
  • Article Number: 747
  • Copyright: © Popovici et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to examine both the feasibility and toxicity of neoadjuvant dose‑dense chemotherapy in women with non‑metastatic breast cancer. A search within the OncoHelp Association breast cancer database has been performed in order to identify all non‑metastatic breast cancer patients who underwent an initial consultation with a medical oncologist between March 2016 and April 2020. The inclusion criteria used were: i) Age, ii) follow‑up care obtained at OncoHelp Association, iii) the intent to treat with a neoadjuvant dose‑dense anthracycline every two weeks for four cycles (C1‑C4) followed by paclitaxel every two weeks for four cycles, with white blood cell growth factor support, and iv) regular anthracycline‑based chemotherapy every three weeks for four cycles, followed by paclitaxel every three weeks for four cycles, v) weight, vi) height, vii) Eastern Cooperative Oncology Group (ECOG) performance status, viii) hemoglobin (Hb) level, ix) Platelet count and x) neutrophil count.
View Figures
View References

Related Articles

Journal Cover

July-2021
Volume 22 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Popovici D, Oprean C, Săftescu S, Negru A, Muntean M, Stanca HT, Teodoru A, Stanca S and Negru Ș: Comparative hematological profiles for dose‑dense vs. regular anthracycline‑based neoadjuvant chemotherapy in non‑metastatic breast cancer. Exp Ther Med 22: 747, 2021
APA
Popovici, D., Oprean, C., Săftescu, S., Negru, A., Muntean, M., Stanca, H.T. ... Negru, Ș. (2021). Comparative hematological profiles for dose‑dense vs. regular anthracycline‑based neoadjuvant chemotherapy in non‑metastatic breast cancer. Experimental and Therapeutic Medicine, 22, 747. https://doi.org/10.3892/etm.2021.10179
MLA
Popovici, D., Oprean, C., Săftescu, S., Negru, A., Muntean, M., Stanca, H. T., Teodoru, A., Stanca, S., Negru, Ș."Comparative hematological profiles for dose‑dense vs. regular anthracycline‑based neoadjuvant chemotherapy in non‑metastatic breast cancer". Experimental and Therapeutic Medicine 22.1 (2021): 747.
Chicago
Popovici, D., Oprean, C., Săftescu, S., Negru, A., Muntean, M., Stanca, H. T., Teodoru, A., Stanca, S., Negru, Ș."Comparative hematological profiles for dose‑dense vs. regular anthracycline‑based neoadjuvant chemotherapy in non‑metastatic breast cancer". Experimental and Therapeutic Medicine 22, no. 1 (2021): 747. https://doi.org/10.3892/etm.2021.10179